Board

Dr Brad Walsh

Dr Brad Walsh

CEO and MD

Brad is the founder of GlyTherix. He has a PhD in protein chemistry, led research groups in government agencies, universities and hospitals and has founded three companies. He was joint recipient of the 2015 Eureka Prize, for Interdisciplinary Research. He has co-authored over 120 peer reviewed papers and book chapters and seven patents.

Dr Nat Lenzo

Dr Nat Lenzo

Non-Executive Director

Dr Lenzo is an Acute/General Medicine Physician and Nuclear Medicine Specialist with interests in Molecular Imaging and Radionuclide Therapy. He has been involved in the concept, development and set up of cyclotron facilities in Perth (2) and Jakarta. He set up the first private theranostic facilities in Australia for targeted radionuclide therapy of cancer at Hollywood Private Hospital, Perth and Macquarie University Hospital, Sydney.

David Burdis

David Burdis

Chief Financial Officer / Company Secretary

A seasoned financial professional having worked in chemical, telecommunications and financial services industries. He has held various senior/board positions, for listed and unlisted companies, in Australia, UK and Hong Kong, including GFA International Limited, Swire Blanch Limited and OAMPS Limited.

Mr Raymore Millard

Mr Raymore Millard

Non-executive Director

Mr Millard is a consultant with extensive experience in providing strategic advice to both listed and unlisted companies in Australia and overseas. He has assisted various companies in raising seed capital and with their ultimate listing. He is similarly assisting the Company.